A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM)
Year: 2018
Type: article
Abstract: Background: Significant advancements, including development of immune checkpoint inhibitors and targeted therapies, have transformed outcomes for patients (pts) with unresectable or metastatic melanoma. However, pts who do not respond or who progress while receiving these regimens have limited options. Spartalizumab (PDR001) is a high-affinity, humanized monoclonal antibody blocking the programmed cell death 1 (PD-1) receptor. This study is evaluating combinations of spartalizumab with novel compounds to restore antitumor T-cell activity in pts with melanoma progressing after prior PD-1 blockade therapy.
Source: Annals of Oncology
Institutions: NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, The University of Sydney, Melanoma Institute Australia, The Netherlands Cancer Institute, Hospital Clínic de Barcelona, University Hospital Zurich, Mount Vernon Cancer Centre, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Institut Gustave Roussy, Novartis (United States), Novartis (Switzerland), Essen University Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2898322281